SCHEMBL1962811

SCHEMBL1962811

CCCCCCN(CCCCCC)C(=O)OC(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 2/20 0.55
CA12 O43570 4/20 0.42
CA1 P00915 4/20 0.42
CA9 Q16790 3/20 0.42
CA2 P00918 1/20 0.42
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC6 Q9UBN7 1/20 0.41
ZDHHC20 Q5W0Z9 2/20 0.39
ZDHHC2 Q9UIJ5 1/20 0.39
MGLL Q99685 1/20 0.39
CA7 P43166 1/20 0.38
HDAC3 O15379 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
MMP8 P22894 1/20 0.37
DNM1 Q05193 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL133198 1.00 CA14 (0.55) CA14CA12CA1CA9CA2
SCHEMBL136485 1.00 CA14 (0.55) CA14CA12CA1CA9CA2
SCHEMBL140146 1.00 CA14 (0.55) CA14CA12CA1CA9CA2
SCHEMBL14755630 0.98 CA14 (0.54) CA14CA12CA1CA9CA2
SCHEMBL26616523 0.96 CA14 (0.53) CA14CA12CA1CA9CA2
SCHEMBL18163279 0.96 CA14 (0.53) CA14CA12CA1CA9CA2
SCHEMBL8021973 0.94 CA14 (0.54) CA14CA12CA1CA9CA2
SCHEMBL18599054 0.94 CA14 (0.54) CA14CA12CA1CA9CA2
SCHEMBL13527824 0.93 CA14 (0.54) CA14CA12CA1CA9CA2
SCHEMBL15801151 0.93 CA14 (0.54) CA14CA12CA1CA9CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295081-A1 IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY ARCTURUS THERAPEUTICS, INC. 2023-09-21 US disclosed
US-8652712-B2 Photoacid generators for extreme ultraviolet lithography INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2014-02-18 US disclosed
US-8039194-B2 Photoacid generators for extreme ultraviolet lithography INTERNATINAL BUSINESS MACHINES CORPORATION (US) 2011-10-18 US disclosed
US-20110143099-A1 Photoacid Generators for Extreme Ultraviolet Lithography INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2011-06-16 US disclosed
US-20090176175-A1 PHOTOACID GENERATORS FOR EXTREME ULTRAVIOLET LITHOGRAPHY INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295081-A1 IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY NSUN3, POLRMT, NPC1L1 CA14 2668/4885CA12 2783/4885CA1 4264/4885
US-20090176175-A1 PHOTOACID GENERATORS FOR EXTREME ULTRAVIOLET LITHOGRAPHY SLC7A5, SLC26A3, SLC1A5 CA14 138/4885CA12 536/4885CA1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.